Avalo Therapeutics, Inc. 10-Q filing
Filed 2026-05-13 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001534120-26-000033
- Form type
- 10-Q
- CIK
- 0001534120
- Primary document
- https://www.sec.gov/Archives/edgar/data/1534120/000153412026000033/avtx-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Avalo Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-20.9M | - | - |
| Net Income | $-19.6M | - | - |
| Eps Basic | -0.98 | - | - |
| Eps Diluted | -0.98 | - | - |
| Cash And Equivalents | $25.0M | - | - |
| Total Assets | $99.9M | - | - |
| Total Liabilities | $31.6M | - | - |
| Shareholders Equity | $68.3M | - | - |
| Operating Cash Flow | $-17.7M | - | - |